Status:
UNKNOWN
Exercise and GLP-1 RA on Insulin Secretion
Lead Sponsor:
University of Copenhagen
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
40-70 years
Phase:
NA
Brief Summary
The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide,...
Detailed Description
The effects of endurance exercise alone or in addition to treatment with glucagon-like- peptide receptor agonists on insulin secretory capacity, will be determined in patients with type 2 diabetes. I...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes
- BMI 28-35
- Moderately preserved insulin secretory capacity (determined by glucagon test)
Exclusion
- Insulin treatment
- Hypertension grade 3
- Heart disease
- Medical history with pancreatitis
- Diagnosed with neuropathy
- Excessive alcohol consumption
- Any condition that would interfere with the protocol.
Key Trial Info
Start Date :
December 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04383197
Start Date
December 10 2019
End Date
August 1 2022
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xlab, Center for Healthy Aging, Department of Biomedical Sciences, University of Copenhagen
Copenhagen, Denmark, 2200